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PPRECLINICAL STUDIES
Pharmacological Inhibition of CB1 Cannabinoid Receptor
Protects Against Doxorubicin-Induced Cardiotoxicity
Partha Mukhopadhyay, PHD,* Sa´ndor Ba´tkai, MD, PHD,* Mohanraj Rajesh, PHD,* Nora Czifra,*
Judith Harvey-White, MSC,* György Hasko´, MD, PHD,† Zsuzsanna Zsengeller, MD, PHD,‡
Norma P. Gerard, MD,‡ Lucas Liaudet, MD,§ George Kunos, MD, PHD, FAHA,*
Pa´l Pacher, MD, PHD, FAPS, FAHA*
Bethesda, Maryland; Newark, New Jersey; Boston, Massachusetts; and Lausanne, Switzerland
Objectives We aimed to explore the effects of pharmacologic inhibition of cannabinoid-1 (CB1) receptor in in vivo and in
vitro models of doxorubicin (DOX)-induced cardiotoxicity.
Background Doxorubicin is one of the most potent antitumor agents available; however, its clinical use is limited because of
the risk of severe cardiotoxicity. Endocannabinoids mediate cardiodepressive effects through CB1 receptors in
various pathophysiological conditions, and these effects can be reversed by CB1 antagonists.
Methods Left ventricular function was measured by Millar pressure-volume system. Apoptosis markers, CB1/CB2 receptor
expression, and endocannabinoid levels were determined by immunohistochemistry, Western blot, reverse
transcription-polymerase chain reaction, real-time polymerase chain reaction, flow cytometry, fluorescent micros-
copy, and liquid chromatography/in-line mass spectrometry techniques.
Results Five days after the administration of a single dose of DOX (20 mg/kg intraperitoneally) to mice, left ventricular
systolic pressure, maximum first derivative of ventricular pressure with respect to time (dP/dt), stroke work,
ejection fraction, cardiac output, and load-independent indexes of contractility (end-systolic pressure–volume
relation, preload-recruitable stroke work, dP/dt–end-diastolic volume relation) were significantly depressed, and
the myocardial level of the endocannabinoid anandamide (but not CB1/CB2 receptor expression) was elevated
compared with vehicle-treated control mice. Treatment with the CB1 antagonists rimonabant or AM281 mark-
edly improved cardiac dysfunction and reduced DOX-induced apoptosis in the myocardium. Doxorubicin also de-
creased cell viability and induced apoptosis in the H9c2 myocardial cell line measured by flow cytometry and
fluorescent microscopy, which were prevented by the preincubation of the cells with either CB1 antagonist, but
not with CB1 and CB2 agonists and CB2 antagonists.
Conclusions These data suggest that CB1 antagonists may represent a new cardioprotective strategy against DOX-induced
cardiotoxicity. (J Am Coll Cardiol 2007;50:528–36) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.03.057i
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coxorubicin (DOX) (adriamycin) is one of the most potent
road-spectrum antitumor anthracycline antibiotics com-
only used to treat a variety of cancers, including severe
eukemias, lymphomas, and solid tumors (1–3). However,
he clinical use of DOX is limited because of its serious
ardiotoxicity, which often leads to irreversible degenerative
ardiomyopathy and heart failure (3).
rom the *Laboratory of Physiological Studies, NIH/NIAAA, Bethesda, Maryland;
Department of Surgery, UMDNJ-New Jersey Medical School, Newark, New Jersey;
Pulmonary Division, Department of Pediatrics, Children’s Hospital, Harvard
edical School, Boston, Massachusetts; and the §Department of Intensive Care
edicine, University Hospital, Lausanne, Switzerland. This study was supported by
he Intramural Research Program of NIH/NIAAA (to Dr. Pacher). Drs. Mukho-
adhyay and Ba´tkai contributed equally to this work.a
Manuscript received December 20, 2006; revised manuscript received February 23,
007, accepted March 6, 2007.The mechanism of DOX-induced cardiotoxicity involves
ncreased oxidative/nitrosative stress (4–7), matrix metal-
oproteinase activation (8,9), and alteration of cardiac
nergetics (10), which eventually lead to cell death by
See page 537
poptosis or cell necrosis (11–15). However, the exact
echanisms have not been fully established, and optimal
herapeutic approaches for cardioprotection remain
ndefined (3).
Endocannabinoids and their synthetic analogs exert
owerful cardiodepressive effects mediated through
annabinoid-1 (CB1) receptors (16,17), which have re-
ently been implicated in the mechanism of hypotension
ssociated with hemorrhagic, endotoxic, and cardiogenic
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August 7, 2007:528–36 CB1 Blockade in DOX-Induced Cardiotoxicityhock, and advanced liver cirrhosis, and these effects can be
revented or reversed by treatment with CB1 antagonists
16,17). Furthermore, the CB1 antagonist rimonabant is
merging as a novel therapeutic agent for obesity and related
ardiometabolic risk factors in humans (17–20). Here, we
Figure 1 Effects of CB1 Antagonists
on DOX-Induced Cardiac Dysfunction
Effect of doxorubicin (DOX) on left ventricular systolic pressure (LVSP), left ven-
tricular end-diastolic pressure (LVEDP), LV maximum first derivative of ventricu-
lar pressure with respect to time (dP/dt), LV dP/dt, heart rate, stroke work,
ejection fraction, and cardiac output and tau (Weiss and Glantz) in mice. Mice
were pretreated either with vehicle, rimonabant, or AM281, and treated with
either vehicle or DOX, as indicated in the Methods section. Hemodynamic
parameters were measured 5 days after DOX administration. Results are mean
 standard error of the mean of 7 to 13 experiments in each group. *p 
0.05 versus vehicle; #p  0.05 versus DOX. CB1  cannabinoid-1.xplore the effects of 2 CB1 antagonists, rimonabant and aM281, on DOX-induced car-
iac dysfunction and cardiotoxic-
ty both in vivo and in vitro.
aterials and Methods
nimals. All protocols were ap-
roved by the Institutional Ani-
al Care and Use Committee
nd were performed in accor-
ance with the National Insti-
utes of Health (NIH) Guide for
he Care and Use of Laboratory
nimals. Male C57BL/6J mice
eighing 25 to 35 g were admin-
stered a single dose of DOX HCl (Sigma/Aldrich, St.
ouis, Missouri) at 20 mg/kg intraperitoneally, and used for
unctional measurements 5 days later when severe cardiac
ysfunction is well established (6,14,15,21,22). Treatment
ith the CB1 antagonists AM281 or rimonabant
SR141716; 10 mg/kg intraperitoneally, respectively)
tarted 1.5 h before the DOX injection and continued (10
g/kg intraperitoneally/day) until the hemodynamic mea-
urements were made.
emodynamic measurements in mice. Left ventricular
erformance was analyzed in mice anesthetized with 2%
soflurane by using 1-F microtip pressure-volume catheter
PVR 1045) and ARIA pressure–volume conductance sys-
em (Millar Instruments, Houston, Texas) coupled to a
owerlab/4SP A/D converter (AD Instruments, Mountain
iew, California) as described (6) (also see the Appendix).
eagents, antibodies, and cell culture. Doxorubicin was
urchased from Sigma Chemical. AM281, AM630,
WH133, and HU210 were purchased from Tocris (Bald-
in, Missouri). SR144528 and rimonabant (SR141716) are
rom the National Institute on Drug Abuse Drug Supply
rogram (Research Triangle Park, North Carolina). Anti-
odies used are anti-actin mAb (Chemicon, Temecula,
alifornia), anti-caspase 3 mAb (Cell Signaling, Danvers,
assachusetts), and anti-active caspase-3 (Cell Signaling).
Rat embryonic ventricular myocardial H9c2 cells were
btained from American Type Culture Collection (Manas-
as, Virginia). Cells were cultured in DMEM (GIBCO,
nvitrogen, Carlsbad, California) containing 10% fetal bo-
ine serum (Invitrogen), 100 U/ml penicillin, and 100
g/ml streptomycin at 37°C in a humidified atmosphere of
% CO2 as described (23). Cells were always used at 80%
f confluence.
Real-time polymerase chain reaction and reverse
ranscription-polymerase chain reaction analyses were per-
ormed from hearts and H9c2 cells for caspase-3, caspase-9,
nd CB1/2 receptor gene expression as detailed in the
ppendix.
estern immunoblot analyses. Protein was extracted
rom tissue homogenates using radioimmunoprecipitation
Abbreviations
and Acronyms
AEA  anandamide
AG  arachidonoylglycerol
CB1/CB2 
cannabinoid-1/-2
DOX  doxorubicin/
adriamycin
I/R  ischemia/
reperfusion
TUNEL  terminal
deoxynucleotidyltransferase-
mediated nick-end labelingssay lysis buffer, containing protease inhibitor cocktail set
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CB1 Blockade in DOX-Induced Cardiotoxicity August 7, 2007:528–36II and phosphatase inhibitor cocktail set I (Calbiochem,
MD Biosciences, San Diego, California). Protein was
easured by Dc protein assay kit (Bio-Rad, Hercules,
alifornia), and equal amounts (40 g per lane) were
ractionated on NuPAGE 4% to 12% Bis-Tris gel (In-
itrogen) and transferred onto nitrocellulose membrane
Invitrogen) using a semidry transfer apparatus (Bio-
ad). The blots were detected with Supersignal West
ico chemiluminescent substrate (Pierce Biotechnology,
ockford, Illinois) and developed using Kodak Biomax
lm (PerkinElmer, Wellesley, Massachusetts). Immuno-
lots were scanned with Epson V750 Pro scanner and
uantification after background correction was carried
ut by ImageQuant5.1 software (GE Healthcare, Pisca-
away, New Jersey); all values were normalized to
eta-actin.
Figure 2 Effect of CB1 Antagonists on DOX-Induced Depression
(A) Representative pressure–volume (P–V) loops obtained with a P–V conductance
in the end-systolic P–V relation (ESPVR) and between mice pretreated with vehicle
DOX-treated mice indicates decreased contractile function, which was improved by
independent indexes of cardiac contractility. Results are mean  standard error o
0.05 versus DOX. EDV  end-diastolic volume relation; ESPVR or Emax  end-sys
ations as in Figure 1.ell viability assay. Cells were seeded at a density of 1 
05 cells in 96 well plates, and cell viability was assessed via
onventional XTT assays (Roche, Indianapolis, Indiana).
fter incubation, the cells were treated for 6 h with XTT
olution at 37°C. The absorbance was measured at 570 nm
sing an enzyme-linked immunosorbent assay reader (Spec-
ramaxPro, Molecular Devices, Union City, California).
low cytometry. Early apoptosis and cytotoxity is deter-
ined by flow cytometry using propidium iodide and
nnexin V staining (Molecular Probes, Invitrogen,
arlsbad, California) according to manufacturer’s recom-
endation. The cells were trypsinized for a very short
ime and collected via centrifugation at 1,000  g for 5
in. The harvested cells were then washed with
hosphate-buffered saline. The cells were resuspended at
density of 1  106 cells/ml in Hank’s balanced salt
oad-Independent Indexes of Cardiac Contractility
ter system at different preloads after vena cava occlusion, showing differences
abant, or AM281 and treated with vehicle or DOX. The less steep ESPVR in
ntagonists. (B) Effects of CB1 antagonists on DOX-induced depression of load-
ean of 9 to 18 experiments in each group. *p  0.05 versus vehicle; #p 
ressure–volume relation; PRSW  preload-recruitable stroke work; other abbrevi-of L
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August 7, 2007:528–36 CB1 Blockade in DOX-Induced Cardiotoxicityolution buffer containing calcium and magnesium.
low-cytometry analyses included 10,000 events using a
ACSCalibur (Becton Dickinson, San Jose, California).
he data were acquired and analyzed using Cell Quest
rogram (Becton Dickinson).
Fluorescence microscopy, DNA fragmentation assay,
yocardial terminal deoxynucleotidyltransferase-mediated
Figure 3 Effects of CB1 Antagonists on DOX-Induced Cell Deat
(A) Effects of CB1 antagonists on cell viability measured by XTT assays. AM281 a
0.05 versus control group; #p  0.05 versus DOX (n  4). (B) Effects of CB1 ant
V-FITC) and cell death detection dye propidium iodide (PI) measured by flow cytom
of CB1 antagonists on active caspase expression (green) and nuclear staining pat
mented in DOX-treated cells (indicative of late apoptosis), but not in CB1 antagoni
Abbreviations as in Figure 1.ick-end labeling (TUNEL) staining, and assay and caspase
activity were used according to manufacturer’s instructions
s described in the Appendix.
easurement of endocannabinoid levels. The levels of
nandamide (AEA) and 2-arachidonoylglycerol (2-AG)
ere quantified by liquid chromatography/in-line mass
pectrometry as detailed in the Appendix.
Apoptosis In Vitro
onabant (1 mol/l) prevent cell death induced by 1 or 5 mol/l of DOX. *p 
ts on the early apoptosis marker fluorescent annexin V conjugate (Annexin
nalysis of H9c2. Representative data from 3 experiments analyzed. (C) Effects
y Hoechst 33342 dye (blue). Please also note that some of the nuclei are frag-
ted or control cells. Representative data from at least 15 experiments analyzed.h and
nd rim
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CB1 Blockade in DOX-Induced Cardiotoxicity August 7, 2007:528–36tatistical analysis. Results are reported as mean  standard
rror of the mean. Probability values of p 0.05 were considered
ignificant. For detailed statistical analysis see the Appendix.
esults
B1 antagonists improve DOX-induced cardiac dys-
unction. Treatment of mice with DOX, 20 mg/kg intra-
eritoneally, induced a significant decrease in heart rate, left
entricular systolic pressure, maximum first derivative of
entricular pressure with respect to time (dP/dt), dP/dt,
troke work, ejection fraction, cardiac output, and load-
ndependent indexes of contractility (preload-recruitable
troke work, dP/dt–end-diastolic volume relation, and end-
ystolic pressure–volume relation, respectively), and an in-
rease in left ventricular end-diastolic pressure and prolon-
ation of relaxation time constants ( Weiss and Glantz)
Figs. 1 and 2). Treatment with rimonabant or AM281 (10
g/kg1 intraperitoneally) immediately before and daily for
days after DOX treatment significantly attenuated the
OX-induced changes in ventricular function (Figs. 1 and
). In vehicle-treated control animals, rimonabant or
M281 exerted no significant effects on the hemodynamic
arameters studied (Fig. 1).
B1 antagonists protect against DOX-induced cell death
n rat embryonic ventricular myocardial-derived H9c2
ells in vitro. Incubation of cells with 1 or 5 mol/l DOX
or 18 h resulted in significant decreases in cell viability,
easured by a colorimetric XTT-based cell viability assay to
8.6  1.6% or 74.4  1.2%, respectively. Doxorubicin-
nduced cell death at 1 and 5 mol/l was completely
revented by 2 h of preincubation (followed by continuous
reatment during the 18 h DOX exposure) with 1 mol/l
M281 (98.0  4.5% and 95.3  5.1%) or rimonabant
96.5  3.6% and 102.0  4.3%, respectively) (Fig. 3A).
annabinoid-1 receptor antagonists alone did not have any
ffect on cell viability (data not shown).
B1 antagonists, but not CB1 and CB2 agonists and CB2
ntagonists, prevent DOX-induced apoptosis in vitro. The
9c2 cell line was subjected to flow cytometric analysis for
poptotic and total dead cells by Annexin V and propidium
odide staining. Early apoptotic marker Annexin V was
ignificantly increased in cells exposed to 1 mol/l DOX for
8 h but remained at control levels in cells pretreated with
ither 1 mol/l AM281 or rimonabant starting from 2 h
efore DOX administration (Fig. 3B). The DOX-induced
otal cell death as indicated by positive propidium iodide
taining (Fig. 3B) confirmed recent cell viability data,
ncluding the higher level of propidium iodide staining in
poptotic compared with normal cells (14). Activation of
aspase is a key downstream event of apoptosis. We mea-
ured the active form of caspase by fluorescence microscopy.
s an indication of caspase activity, green color is generated
y cleavage of a generic caspase substrate (rhodamine 110,
is-[L-aspartic acid amide], trifluoroacetic acid salt) intro-
uced into live cells. The green color was conspicuouslyresent in all DOX-treated H9c2 cells (Fig. 3C). In
ontrast, the green fluorescence was completely absent in
ells treated with 1 mol/l AM281 or rimonabant. We
imultaneously measured the late apoptotic marker repre-
ented as fragmented nuclei using Hoechst 33342 staining
Molecular Probes, Invitrogen). Few fragmented nuclei
ere observed in DOX-treated cells whereas no such nuclei
ere present in normal, AM281, or rimonabant pretreated
amples. Thus, pretreatment with either AM281 or rimon-
bant protects H9c2 cells from DOX-induced apoptosis as
hown by early-to-late apoptotic markers.
Pretreatment for 2 h (followed by continuous treat-
ent during the 18 h DOX exposure) with CB2 agonist
Figure 4 Effects of CB1 Agonist, CB2 Antagonists, and
Agonists on DOX-Induced Apoptosis in H9c2 In Vitro
Effects of CB1 agonist, CB2 antagonists, and agonists on the early apoptosis
marker Annexin V-FITC and cell death detection dye propidium iodide (PI) mea-
sured by flow cytometric analysis of H9c2. Representative data from 3 experi-
ments analyzed. Abbreviations as in Figures 1 and 3.
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August 7, 2007:528–36 CB1 Blockade in DOX-Induced CardiotoxicityWH133, CB1 agonist HU210, CB2 antagonists (AM630
nd SR144528) (1 mol/l each) did not have any protective
ffect against DOX-induced cell death and apoptosis (Fig.
). Interestingly, CB1 agonist HU210 by itself significantly
nhanced apoptosis (Fig. 4).
B1 antagonists prevent DOX-induced apoptosis of
ardiomyocytes in vivo. Myocardial caspase-3-dependent
poptosis was previously described in the mouse model of
OX-induced heart failure (14,24). We have observed signif-
cant level of cleaved caspase-3 in samples of heart tissue from
OX-treated mice. Two representative samples from each
roup are shown in Figure 5A. The total absence of cleaved
aspase-3 in AM281 or rimonabant pretreated mice indicates
he protective effect of CB1 antagonists against apoptosis.
As shown in Figure 5B, DOX treatment induced marked
levation in the caspase-3 activity in the myocardial tissues
Figure 5 Effects of CB1 Antagonists on DOX-Induced Apoptosis
(A) Effects of CB1 antagonists on DOX-induced caspase-3 activation analyzed by W
reduced myocardial caspase-3 activation in DOX-treated mice. The blot was also p
ments. (B) Effects of CB1 antagonists on DOX-induced caspase-3 activity analyzed
AM281 reduced caspase-3 activity in DOX-treated mice. *p  0.05 versus vehicle
induced caspase-3 and caspase-9 gene expression. Data were analyzed with 2 ho
ment with rimonabant or AM281 reduced myocardial caspase-3 and caspase-9 ge
(n  6 to 15 per group). Abbreviations as in Figure 1.2.8-fold) compared with control mice. Rimonabant/
M281 pretreatment of mice prevented the DOX-induced
ncrease in caspase-3 activity.
We also analyzed gene expression of 2 apoptotic markers,
aspase-3 and caspase-9, from the same group of heart
amples. In agreement with the increased protein expression,
aspase-3 mRNA was also increased significantly by DOX
reatment to 4.5  0.7-fold over control group, and this
ncrease was markedly attenuated by AM281 or rimonabant
retreatment (1.6 0.2 and 0.9 0.2, respectively) (Fig. 5C).
oxorubicin also induced a 10.4  1.6-fold increase in
aspase-9 gene expression compared with normal hearts, which
as reduced by pretreatment with AM281 or rimonabant to a
.8  0.6 and 2.1  0.6-fold change, respectively. In vehicle-
reated control mice, AM281 or rimonabant treatment did not
ffect caspase-3 and caspase-9 gene expression.
ivo
n blot from heart tissue homogenates. Treatment with rimonabant or AM281
for beta-actin level for loading control. Representative blot from at least 5 experi-
lorimetric method from heart tissue homogenates. Treatment with rimonabant or
0.05 versus DOX (n  4 per group). (C) Effects of CB1 antagonists on DOX-
eping genes, and data presented here were normalized with beta-actin. Treat-
ression in DOX-treated mice. *p  0.05 versus vehicle; #p  0.05 versus DOXIn V
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CB1 Blockade in DOX-Induced Cardiotoxicity August 7, 2007:528–36B1 receptor antagonists attenuate DOX-induced DNA
ragmentation. Doxorubicin also increased myocardial
UNEL staining in the myocardium, which was largely
ttenuated by either rimonabant or AM281 pretreatment
Fig. 6A).
To strengthen the preceding conclusion, we used 2
dditional quantitative methods. Doxorubicin-induced
NA fragmentations in the myocardial tissue was increased
.9- and 4.5-fold compared with sham control measured by
uantitative TUNEL and DNA fragmentation assays, and
as largely attenuated by pretreatment with CB1 antago-
ists (Figs. 6B and 6C).
ffects of DOX on myocardial CB1 and CB2 recep-
ors. Myocardial CB1 receptor protein levels were un-
hanged in DOX-treated mice as documented by using
estern blots (Fig. 7A). The specificity of the antibodies
sed was confirmed by the absence of a specific band using
yocardial tissue from a CB1 knockout mouse. Myocar-
ial CB1 or CB2 receptor gene expression was not affected
y DOX treatment in mice as verified using reverse
ranscription-polymerase chain reaction (Fig. 7B) as well as
uantitative real-time polymerase chain reaction where
Figure 6 Effects of Rimonabant and AM281 on DOX-Induced M
Apoptosis In Vivo Determined by TUNEL and DNA Frag
(A) Note the increased myocardial terminal deoxynucleotidyltransferase-mediated
ment with cannabinoid-1 antagonist rimonabant and AM281 reduced myocardial T
n  3 hearts per group. Quantitative measurements were carried out in 20 fields
rimonabant and AM281 on DOX-induced myocardial apoptosis in vivo by TUNEL as
of rimonabant and AM281 on DOX-induced deoxyribonucleic acid (DNA) fragmentat
treated mice (100%). *p  0.05 versus vehicle; #p  0.05 versus DOX (n  4 pehe CB1 or CB2 receptor gene expressions were normal-
zed to beta-actin gene expression (Fig. 7C). Similar
esults were obtained in cardiomyocytes (Fig. 7D, lower
art).
OX increased endocannabinoid AEA content both in
ivo and in vitro. Doxorubicin treatment resulted in in-
reased AEA but not 2-AG content in the myocardium
Fig. 7E). Similarly, elevated AEA levels were detected in
OX-treated H9c2 cells as compared with the vehicle-
reated control cells (Fig. 7F).
iscussion
he natural ligands of CB1 receptors are the endocan-
abinoids AEA and 2-AG, both of which are present in
he myocardium, along with CB1 receptors (16,17).
umerous previous experimental studies have demon-
trated that activation of the endocannabinoid system
ay contribute to the hypotension and compromised
ardiovascular function in a variety of pathophysiological
tates (e.g., hemorrhagic, endotoxic, and cardiogenic
hock, advanced liver cirrhosis, and cirrhotic cardiomy-
rdial
tation Assay
d labeling (TUNEL) staining from doxorubicin (DOX)-treated mice (brown). Treat-
taining in DOX-treated mice. Similar immunohistochemical profiles were seen in
up. *p  0.05 versus vehicle (Veh); #p  0.05 versus DOX. (B) Effects of
p  0.05 versus vehicle; #p  0.05 versus DOX (n  4 per group). (C) Effects
vivo. Changes are expressed in % of myocardial DNA fragmentation in vehicle-
p). Eu  Europium.yoca
men
nick-en
UNEL s
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August 7, 2007:528–36 CB1 Blockade in DOX-Induced Cardiotoxicitypathy) through the activation of myocardial and vascular
B1 receptors. Importantly, in all these conditions, the
ardiovascular depressive effects could be prevented or
eversed by various CB1 antagonists (16,17).
Our present findings provide evidence that endocannabi-
Figure 7 Effects of DOX on Myocardial Endocannabinoid
Content and CB1/2 Receptor Expression
(A) Evidence of CB1 receptor protein expression in total lysate of DOX-treated
mouse heart tissue homogenate by Western blot analysis. (B and D) Evidence
of CB1 and CB2 receptor gene expression by semiquantitative reverse tran-
scription-polymerase chain reaction (RT-PCR) from complementary deoxyribonucleic
acid of both untreated and DOX-treated mouse heart samples (B) and cardiomyo-
cytes (D). (C) Evidence of CB1 receptor and CB2 receptor gene expression in heart
tissue by quantitative real-time PCR after normalization to beta-actin (n  6 to 15).
(E) Effect of DOX on anandamide (AEA) and 2-arachidonylglycerol (2-AG) production
in vivo by liquid chromatography mass spectrometry (LCMS) analysis of heart tis-
sue samples. *p  0.05 versus vehicle (n  6). (F) Effect of DOX (1 M for 2 h)
on AEA and 2-AG production in vitro by LCMS analysis of H9c2 cells. Increased
AEA levels were observed in doxorubicin treated samples. *p  0.05 versus vehi-
cle (n  3). KO  knockout; other abbreviations as in Figure 1.oid AEA is overproduced in a well-established model of nOX-induced acute heart failure, and CB1 antagonists
mprove compromised contractile function. Furthermore,
e show that CB1 antagonists exert powerful cytoprotective
ffect in cardiomyocytes against DOX-induced cardiotoxic-
ty both in vivo and in vitro by reducing apoptosis, offering
novel approach for the prevention of this devastating
omplication of chemotherapy.
There is limited and conflicting information about the
ole of cannabinoid receptor activation in cell-protective
echanisms against ischemia/reperfusion (I/R) damage in
he heart (16,17,25). A major limitation of these studies is
he use of buffer-perfused isolated heart preparations, in
hich the effects of endocannabinoids and synthetic ago-
ists on immune cells, which are pivotal in reperfusion
amage, cannot be studied, as well as the use of nonselective
annabinoid ligands. In a more relevant in vivo model of
yocardial I/R injury induced by coronary occlusion/
eocclusion in anesthetized mice, the published evidence
oints to the protective role of CB2 but not CB1 receptor
ctivation (CB2 activation on immune cells was responsible
or the reduced leukocyte-dependent myocardial damage
ssociated with reperfusion) (26). The presence of CB2
eceptors in the myocardium and their function has never
een convincingly demonstrated so far (selective CB2 recep-
or agonists do not decrease blood pressure and myocardial
ontractility in vivo, in contrast to the well-known hypo-
ensive and cardiodepressive effects of CB1 agonists). Two
tudies using rat models of acute and chronic myocardial
nfarction have demonstrated that endocannabinoids con-
ribute to the hypotension and cardiodepression associated
ith acute cardiogenic shock, which could be attenuated by
B1 antagonists (27,28). Cannabinoid-1 receptor antago-
ist AM251 was suggested to promote remodeling in the
ater chronic heart failure study, but it tended to improve
urvival. In contrast, the treatment with CB1 agonist
U210 was shown to prevent endothelial dysfunction, but
t increased left ventricular end-diastolic pressure (28).
owever, the major limitation of the previous study (28) is
he use of high dose of HU210, which was previously
eported to cause severe psychotropic side effects and hypo-
hermia, and the use of suboptimal doses of CB1 antagonist
M251 (17). Furthermore, HU210 was previously demon-
trated to exert antiarrhythmic, anti-inflammatory proper-
ies, and to decrease myocardial damage in perfused hearts
y mechanisms not related to CB1 activation, complicating
he interpretation of these results (17).
In our present study, we used a well-established mouse
odel of DOX-induced acute heart failure in which the
ardiac dysfunction has been characterized by using either
chocardiography (14,21), tissue Doppler imaging (22), or
ressure–volume systems (6,15). Importantly, in this model,
direct correlation between the degree of myocardial
poptosis and the severity of DOX-induced heart failure has
een established (22). Apoptotic cell death is a key compo-
ent in DOX-induced cardiotoxicity as established by
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he present findings.
Here we demonstrate that pharmacologic inhibition of
B1 receptors with rimonabant and AM281 conferred
arked protection against DOX-induced cardiac dysfunc-
ion and cell death both in vivo and in vitro. The protective
ffect against DOX-induced cell death was not observed
ith CB1 and CB2 agonists and CB2 antagonists in vitro.
hus, CB1 antagonists may protect against DOX-induced
ardiotoxicity by exerting potent cytoprotective effects on
he one hand, and by antagonizing the cardiodepression
licited by endocannabinoid AEA on the other.
The observed protective effect of CB1 antagonists and the
OX-induced increase in myocardial AEA content may,
herefore, suggest that DOX-induced cardiotoxicity is associ-
ted with and mediated, at least in part, by activation of the
ndocannabinoid system. Collectively, the present findings
uggest that CB1 antagonists may represent a new cardiopro-
ective strategy against DOX-induced cardiotoxicity and per-
aps other cardiovascular pathologies associated with increased
ell death. Further studies are warranted to investigate the
nderlying signaling mechanisms of these beneficial effects.
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